Comparison of procarbazine, imidazole-carboxyamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate

J. D. Schmidt, W. W. Scott, R. P. Gibbons, D. E. Johnson, G. R. Prout, S. A. Loening, M. S. Soloway, T. M. Chu, J. F. Gaeta, N. H. Slack, J. Saroff, G. P. Murphy

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

In this third cooperative chemotherapy trial 165 patients with histologically confirmed, relapsing clinical stage D cancer were randomized to receive either imidazole-carboxamide, procarbazine or cyclophosphamide. All patients had received and failed previous hormonal therapy. Patients whose disease progressed after 12 weeks on initial therapy were crossed over or randomized to receive an alternate drug. There were 129 patients available for comparison of treatments. The objective response rates (partial regression plus stable disease) were 26 per cent for cyclophosphamide, 27 per cent for imidazole-carboxamide and 14 per cent for procarbazine. Subjective responses were noted in pain relief, improvement in performance status and weight gain. Procarbazine was associated with excessive toxicity, resulting in many patients (28 per cent) discontinuing therapy within the first 3 weeks and closure of this particular arm of the study. The regimen of initial imidazole-carboxamide therapy with a later cross-over to cyclophosphamide when the disease continues to progress is associated with the longest increase in survival. Imidazole-carboxamide and cyclophosphamide appear to be active agents in advanced prostatic cancer and are worthy of continued use in this disease.

Original languageEnglish
Pages (from-to)185-189
Number of pages5
JournalJournal of Urology
Volume121
Issue number2
StatePublished - Dec 1 1979
Externally publishedYes

Fingerprint

Procarbazine
Cyclophosphamide
Prostate
Carcinoma
Therapeutics
Weight Gain
Prostatic Neoplasms
imidazole
Drug Therapy
Pain
Survival
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Schmidt, J. D., Scott, W. W., Gibbons, R. P., Johnson, D. E., Prout, G. R., Loening, S. A., ... Murphy, G. P. (1979). Comparison of procarbazine, imidazole-carboxyamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. Journal of Urology, 121(2), 185-189.

Comparison of procarbazine, imidazole-carboxyamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. / Schmidt, J. D.; Scott, W. W.; Gibbons, R. P.; Johnson, D. E.; Prout, G. R.; Loening, S. A.; Soloway, M. S.; Chu, T. M.; Gaeta, J. F.; Slack, N. H.; Saroff, J.; Murphy, G. P.

In: Journal of Urology, Vol. 121, No. 2, 01.12.1979, p. 185-189.

Research output: Contribution to journalArticle

Schmidt, JD, Scott, WW, Gibbons, RP, Johnson, DE, Prout, GR, Loening, SA, Soloway, MS, Chu, TM, Gaeta, JF, Slack, NH, Saroff, J & Murphy, GP 1979, 'Comparison of procarbazine, imidazole-carboxyamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate', Journal of Urology, vol. 121, no. 2, pp. 185-189.
Schmidt JD, Scott WW, Gibbons RP, Johnson DE, Prout GR, Loening SA et al. Comparison of procarbazine, imidazole-carboxyamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. Journal of Urology. 1979 Dec 1;121(2):185-189.
Schmidt, J. D. ; Scott, W. W. ; Gibbons, R. P. ; Johnson, D. E. ; Prout, G. R. ; Loening, S. A. ; Soloway, M. S. ; Chu, T. M. ; Gaeta, J. F. ; Slack, N. H. ; Saroff, J. ; Murphy, G. P. / Comparison of procarbazine, imidazole-carboxyamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. In: Journal of Urology. 1979 ; Vol. 121, No. 2. pp. 185-189.
@article{ea9051bc47c94003ba3547ccf1c5b1e2,
title = "Comparison of procarbazine, imidazole-carboxyamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate",
abstract = "In this third cooperative chemotherapy trial 165 patients with histologically confirmed, relapsing clinical stage D cancer were randomized to receive either imidazole-carboxamide, procarbazine or cyclophosphamide. All patients had received and failed previous hormonal therapy. Patients whose disease progressed after 12 weeks on initial therapy were crossed over or randomized to receive an alternate drug. There were 129 patients available for comparison of treatments. The objective response rates (partial regression plus stable disease) were 26 per cent for cyclophosphamide, 27 per cent for imidazole-carboxamide and 14 per cent for procarbazine. Subjective responses were noted in pain relief, improvement in performance status and weight gain. Procarbazine was associated with excessive toxicity, resulting in many patients (28 per cent) discontinuing therapy within the first 3 weeks and closure of this particular arm of the study. The regimen of initial imidazole-carboxamide therapy with a later cross-over to cyclophosphamide when the disease continues to progress is associated with the longest increase in survival. Imidazole-carboxamide and cyclophosphamide appear to be active agents in advanced prostatic cancer and are worthy of continued use in this disease.",
author = "Schmidt, {J. D.} and Scott, {W. W.} and Gibbons, {R. P.} and Johnson, {D. E.} and Prout, {G. R.} and Loening, {S. A.} and Soloway, {M. S.} and Chu, {T. M.} and Gaeta, {J. F.} and Slack, {N. H.} and J. Saroff and Murphy, {G. P.}",
year = "1979",
month = "12",
day = "1",
language = "English",
volume = "121",
pages = "185--189",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of procarbazine, imidazole-carboxyamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate

AU - Schmidt, J. D.

AU - Scott, W. W.

AU - Gibbons, R. P.

AU - Johnson, D. E.

AU - Prout, G. R.

AU - Loening, S. A.

AU - Soloway, M. S.

AU - Chu, T. M.

AU - Gaeta, J. F.

AU - Slack, N. H.

AU - Saroff, J.

AU - Murphy, G. P.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - In this third cooperative chemotherapy trial 165 patients with histologically confirmed, relapsing clinical stage D cancer were randomized to receive either imidazole-carboxamide, procarbazine or cyclophosphamide. All patients had received and failed previous hormonal therapy. Patients whose disease progressed after 12 weeks on initial therapy were crossed over or randomized to receive an alternate drug. There were 129 patients available for comparison of treatments. The objective response rates (partial regression plus stable disease) were 26 per cent for cyclophosphamide, 27 per cent for imidazole-carboxamide and 14 per cent for procarbazine. Subjective responses were noted in pain relief, improvement in performance status and weight gain. Procarbazine was associated with excessive toxicity, resulting in many patients (28 per cent) discontinuing therapy within the first 3 weeks and closure of this particular arm of the study. The regimen of initial imidazole-carboxamide therapy with a later cross-over to cyclophosphamide when the disease continues to progress is associated with the longest increase in survival. Imidazole-carboxamide and cyclophosphamide appear to be active agents in advanced prostatic cancer and are worthy of continued use in this disease.

AB - In this third cooperative chemotherapy trial 165 patients with histologically confirmed, relapsing clinical stage D cancer were randomized to receive either imidazole-carboxamide, procarbazine or cyclophosphamide. All patients had received and failed previous hormonal therapy. Patients whose disease progressed after 12 weeks on initial therapy were crossed over or randomized to receive an alternate drug. There were 129 patients available for comparison of treatments. The objective response rates (partial regression plus stable disease) were 26 per cent for cyclophosphamide, 27 per cent for imidazole-carboxamide and 14 per cent for procarbazine. Subjective responses were noted in pain relief, improvement in performance status and weight gain. Procarbazine was associated with excessive toxicity, resulting in many patients (28 per cent) discontinuing therapy within the first 3 weeks and closure of this particular arm of the study. The regimen of initial imidazole-carboxamide therapy with a later cross-over to cyclophosphamide when the disease continues to progress is associated with the longest increase in survival. Imidazole-carboxamide and cyclophosphamide appear to be active agents in advanced prostatic cancer and are worthy of continued use in this disease.

UR - http://www.scopus.com/inward/record.url?scp=0018742759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018742759&partnerID=8YFLogxK

M3 - Article

C2 - 370420

AN - SCOPUS:0018742759

VL - 121

SP - 185

EP - 189

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -